Chemistry:Clemastine
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682542 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 39.2% |
| Metabolism | Hepatic |
| Elimination half-life | 21.3 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H26ClNO |
| Molar mass | 343.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Clemastine, also known as meclastin, is a first-generation H1 histamine antagonist (antihistamine) with anticholinergic properties (drying) and sedative side effects.[1] Like all first-generation antihistamines, it is sedating.[2][3]
Patented in 1960, it came into medical use in 1967.[4]
Medical uses
Clemastine is used to relieve hay fever and allergy symptoms, including sneezing; runny nose; and red, itchy, tearing eyes. Prescription strength clemastine is also used to relieve the itching and swelling of hives.[5]
Side effects
Overdosage symptoms are paradoxical, ranging from CNS depression to stimulation. Stimulation is most common in children, and is usually followed by excitement, hallucinations, ataxia, loss of coordination, muscle twitching, athetosis, hyperthermia, cyanosis, convulsions, tremors, and hyperreflexia. This may be followed by postictal depression and cardiovascular/respiratory arrest. Other common overdose symptoms include dry mouth, fixed dilated pupils, flushing of the face, and pyrexia. In adults, overdose usually leads to CNS depression, ranging from drowsiness to coma.[6]
Continuous and/or cumulative use of anticholinergic medications, including first-generation antihistamines, is associated with higher risk of cognitive decline and dementia in older people.[7][8]
Pharmacology
Clemastine is an antihistamine with anticholinergic and sedative effects. Antihistamines competitively bind to histamine receptor sites, thus reducing the neurotransmitter's effects. Effects of histamine (which are countered by antihistamines) include:
- Increased capillary permeability
- Increased capillary dilatation
- Edema (i.e., swelling)
- Pruritus (Itch)
- Gastrointestinal/respiratory smooth muscle constriction
Clemastine inhibits both the vasoconstrictor and vasodilator effects of histamine. Depending on the dose, the drug can produce paradoxical effects, including CNS stimulation or depression.
Most antihistamines exhibit some type of anticholinergic activity. Antihistamines act by competitively binding to H1-receptor sites, thus blocking the binding of endogenous histamine. Antihistamines do not chemically inactivate or prevent the normal release of histamine.
Clemastine does also act as FIASMA (functional inhibitor of acid sphingomyelinase).[9]
Clemastine is rapidly absorbed from the gastrointestinal tract and peak plasma concentrations are attained in 2–4 hours. Antihistamines are thought to be metabolized in the liver, mostly by mono-/didemethylation and glucuronide conjugation. It is an inhibitor of cytochrome P450 CYP2D6 and may interfere with other drugs metabolized by this isozyme.
Mechanism of action
Clemastine is a selective histamine H1 antagonist. It binds to the histamine H1 receptor, thus blocking the action of endogenous histamine, which leads to temporary relief of the negative symptoms caused by histamine.
Society and culture
Clemastine is an OTC drug, and is available under many names and dosage forms worldwide. Most common brand name is Tavegyl.[10]
References
- ↑ "Clemastine". https://www.drugbank.ca/drugs/DB00283.
- ↑ "Perspectives on Second-Generation OTC Antihistamines". 2012-03-30. https://www.pharmacytimes.com/p2p/perspectives-on-second-generation-otc-antihistamines.
- ↑ "Allergic rhinitis--current pharmacotherapy". Otolaryngologic Clinics of North America 41 (2): 347–58, vii. April 2008. doi:10.1016/j.otc.2007.11.014. PMID 18328373.
- ↑ (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 547. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA547.
- ↑ "Clemastine". https://medlineplus.gov/druginfo/meds/a682542.html.
- ↑ "Clemastine Side Effects: Common, Severe, Long Term". 23 January 2023. https://www.drugs.com/sfx/clemastine-side-effects.html.
- ↑ "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study". JAMA Internal Medicine 175 (3): 401–407. March 2015. doi:10.1001/jamainternmed.2014.7663. PMID 25621434.
- ↑ "Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study". Archives of Internal Medicine 169 (14): 1317–1324. July 2009. doi:10.1001/archinternmed.2009.229. PMID 19636034.
- ↑ "Identification of novel functional inhibitors of acid sphingomyelinase". PLOS ONE 6 (8): e23852. 2011. doi:10.1371/journal.pone.0023852. PMID 21909365. Bibcode: 2011PLoSO...623852K.
- ↑ drugs.com Clemastine at drugs.com international listings Page accessed May 10, 2015
External links
- NIH Medline Plus listing on Clemastine
- The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations
 |  |
